Table 1 Clinical and laboratory characteristics of the AML group (n = 91)
From: Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia
General characteristics | |
|---|---|
Age (years) | 33 (18–65) |
TLC (× 103/mm3) | 38.9 (1–440) |
Hb (g/dl) | 8 (2.3–13) |
PLT (× 103/mm3) | 35 (5–297) |
PB blast (%) | 50 (0–98) |
BM blast (%) | 70 (14–97) |
Sex | |
Male | 50 (54.9%) |
Female | 41 (45.1%) |
Clinical data | |
Hepatomegaly | 27 (29.7%) |
Splenomegaly | 23 (25.3%) |
Lymphadenopathy | 30 (33.0%) |
BM cellularity | |
Hypercellular | 70 (76.9) |
Hypocellular | 7 (7.7) |
Normocellular | 14 (15.4) |
FAB classification | |
M1 | 11 (12.1%) |
M2 | 38 (41.8%) |
M4 | 24 (26.4%) |
M5 | 17 (18.6%) |
M7 | 1 (1.1%) |
MPO | |
Positive | 88 (96.7%) |
CD13 | |
Positive | 91 (100.0%) |
CD33 | |
Positive | 91 (100.0%) |
CD14 | |
Positive | 44 (48.4%) |
CD61 | |
Positive | 1 (1.1%) |
Aberrant IPT markers | |
Without marker | 73 (80.2%) |
With marker | 18 (19.8%) |
IPT | |
Myeloid | 52 (57.1%) |
Monocytic | 7 (7.7%) |
Myelomonocytic | 31 (34.0%) |
Megakaryoblastic | 1 (1.1%) |
FLT3(ITD) | |
Mutant | 14 (15.4%) |
Wild | 77 (84.6%) |
Cytogenetic risk | |
Favorable | 14 (15.4%) |
Intermediate | 61 (67.0%) |
Adverse | 16 (17.6%) |